| Primary |
| Renal Transplant |
23.6% |
| Stem Cell Transplant |
10.1% |
| Immunosuppression |
9.4% |
| Prophylaxis Against Graft Versus Host Disease |
8.7% |
| Liver Transplant |
5.6% |
| Heart Transplant |
5.1% |
| Bone Marrow Transplant |
4.6% |
| Cord Blood Transplant Therapy |
4.5% |
| Lung Transplant |
3.6% |
| Immunosuppressant Drug Therapy |
3.5% |
| Prophylaxis Against Transplant Rejection |
3.1% |
| Nephrotic Syndrome |
3.1% |
| Aplastic Anaemia |
2.8% |
| Product Used For Unknown Indication |
2.6% |
| Graft Versus Host Disease |
2.3% |
| Drug Use For Unknown Indication |
2.1% |
| Interstitial Lung Disease |
1.4% |
| Prophylaxis |
1.3% |
| Hypertension |
1.3% |
| Psoriasis |
1.2% |
|
| Sepsis |
8.8% |
| Pyrexia |
8.2% |
| Thrombotic Microangiopathy |
7.9% |
| Renal Impairment |
7.4% |
| Vomiting |
6.6% |
| Transplant Rejection |
6.5% |
| White Blood Cell Count Decreased |
5.1% |
| Reversible Posterior Leukoencephalopathy Syndrome |
5.0% |
| Renal Failure |
4.5% |
| Weight Decreased |
4.5% |
| Infection |
4.2% |
| Respiratory Failure |
4.1% |
| Weight Increased |
3.8% |
| Tubulointerstitial Nephritis |
3.7% |
| Graft Versus Host Disease |
3.6% |
| White Blood Cell Count Increased |
3.4% |
| Renal Failure Acute |
3.4% |
| Thrombocytopenia |
3.3% |
| Rhabdomyolysis |
3.1% |
| Leukoencephalopathy |
3.0% |
|
| Secondary |
| Renal Transplant |
14.8% |
| Immunosuppression |
12.5% |
| Product Used For Unknown Indication |
10.6% |
| Prophylaxis Against Graft Versus Host Disease |
9.8% |
| Stem Cell Transplant |
6.7% |
| Drug Use For Unknown Indication |
6.0% |
| Prophylaxis Against Transplant Rejection |
5.4% |
| Heart Transplant |
4.1% |
| Bone Marrow Conditioning Regimen |
3.9% |
| Prophylaxis |
3.3% |
| Bone Marrow Transplant |
3.1% |
| Immunosuppressant Drug Therapy |
2.7% |
| Graft Versus Host Disease |
2.5% |
| Cord Blood Transplant Therapy |
2.5% |
| Psoriasis |
2.2% |
| Hypertension |
2.1% |
| Nephrotic Syndrome |
2.1% |
| Acute Myeloid Leukaemia |
2.1% |
| Liver Transplant |
1.9% |
| Aplastic Anaemia |
1.6% |
|
| Urinary Tract Infection |
10.5% |
| Sepsis |
10.3% |
| Transplant Rejection |
5.9% |
| Therapeutic Agent Toxicity |
5.9% |
| Pyrexia |
5.7% |
| Rhabdomyolysis |
5.6% |
| Renal Impairment |
5.5% |
| Basal Cell Carcinoma |
5.5% |
| Vomiting |
5.3% |
| Cytomegalovirus Infection |
4.2% |
| Weight Decreased |
4.2% |
| Renal Failure |
4.0% |
| Renal Failure Acute |
4.0% |
| Thrombocytopenia |
3.5% |
| Ureteric Stenosis |
3.5% |
| Venoocclusive Liver Disease |
3.4% |
| Graft Versus Host Disease |
3.3% |
| Venoocclusive Disease |
3.3% |
| Respiratory Failure |
3.2% |
| Cholelithiasis |
3.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
17.0% |
| Prophylaxis Against Graft Versus Host Disease |
9.7% |
| Drug Use For Unknown Indication |
8.5% |
| Prophylaxis |
7.9% |
| Bone Marrow Conditioning Regimen |
7.4% |
| Stem Cell Transplant |
7.1% |
| Aplastic Anaemia |
5.5% |
| Infection Prophylaxis |
4.7% |
| Psoriasis |
4.6% |
| Rheumatoid Arthritis |
3.6% |
| Hypertension |
3.2% |
| Immunosuppression |
3.1% |
| Antifungal Prophylaxis |
2.9% |
| Premedication |
2.7% |
| Prophylaxis Against Transplant Rejection |
2.5% |
| Acute Myeloid Leukaemia |
2.4% |
| Graft Versus Host Disease |
2.0% |
| Renal Transplant |
1.9% |
| Antiviral Prophylaxis |
1.6% |
| Prophylaxis Of Nausea And Vomiting |
1.4% |
|
| Vomiting |
9.5% |
| Sepsis |
9.5% |
| Pyrexia |
7.8% |
| Venoocclusive Liver Disease |
6.2% |
| Death |
5.4% |
| Acute Graft Versus Host Disease |
5.2% |
| Thrombocytopenia |
5.1% |
| Drug Ineffective |
4.8% |
| Therapeutic Response Decreased |
4.6% |
| Renal Failure |
4.4% |
| Respiratory Failure |
4.3% |
| Graft Versus Host Disease |
4.2% |
| Weight Decreased |
4.2% |
| Pneumonia |
3.9% |
| White Blood Cell Count Decreased |
3.7% |
| Weight Increased |
3.6% |
| Chronic Graft Versus Host Disease |
3.5% |
| Thrombotic Microangiopathy |
3.5% |
| Infection |
3.4% |
| Renal Impairment |
3.4% |
|
| Interacting |
| Product Used For Unknown Indication |
17.3% |
| Renal Transplant |
12.5% |
| Immunosuppression |
10.1% |
| Drug Use For Unknown Indication |
6.5% |
| Nephrotic Syndrome |
6.0% |
| Heart Transplant |
5.9% |
| Hiv Infection |
5.4% |
| Hypertension |
5.1% |
| Gout |
4.5% |
| Immunosuppressant Drug Therapy |
4.5% |
| Pyrexia |
3.6% |
| Pneumonia |
3.3% |
| Prophylaxis |
2.7% |
| Graft Versus Host Disease |
1.9% |
| Prophylaxis Against Graft Versus Host Disease |
1.9% |
| Stem Cell Transplant |
1.9% |
| Stomatitis |
1.8% |
| Infection Prophylaxis |
1.7% |
| Nausea |
1.7% |
| Skin Lesion |
1.7% |
|
| Drug Interaction |
24.5% |
| Immunosuppressant Drug Level Increased |
14.7% |
| Rhabdomyolysis |
7.7% |
| Vomiting |
4.9% |
| Tenderness |
4.2% |
| Weaning Failure |
4.2% |
| Aspartate Aminotransferase Increased |
3.5% |
| Fatigue |
3.5% |
| International Normalised Ratio Increased |
3.5% |
| Pain In Extremity |
3.5% |
| Posterior Reversible Encephalopathy Syndrome |
3.5% |
| Drug Level Decreased |
2.8% |
| Maternal Exposure During Pregnancy |
2.8% |
| Renal Impairment |
2.8% |
| Skin Toxicity |
2.8% |
| Tremor |
2.8% |
| Generalised Oedema |
2.1% |
| Guillain-barre Syndrome |
2.1% |
| Haematochezia |
2.1% |
| Malaise |
2.1% |
|
